{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:34:02Z","timestamp":1784878442518,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ijid.2024.107357","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T17:23:51Z","timestamp":1734024231000},"page":"107357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem\/cilastatin\/relebactam (IMI\/REL) vs piperacillin\/tazobactam (PIP\/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)"],"prefix":"10.1016","volume":"153","author":[{"given":"Junjie","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianshu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke Francis","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatka","family":"Iamboliyska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2209-5288","authenticated-orcid":false,"given":"Sandra","family":"Koseoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieming","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2024.107357_bib0001","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13054-022-04192-w","article-title":"Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired\/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane\/tazobactam versus meropenem","volume":"26","author":"Kollef","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.ijid.2024.107357_bib0002","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/crj.12036","article-title":"Differences in incidence and outcome of ventilator-associated pneumonia in surgical and medical ICUs in a tertiary hospital in China","volume":"8","author":"Song","year":"2014","journal-title":"Clin Respir J"},{"key":"10.1016\/j.ijid.2024.107357_bib0003","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1097\/01.CCM.0000181731.53912.D9","article-title":"Clinical and economic consequences of ventilator-associated pneumonia: a systematic review","volume":"33","author":"Safdar","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijid.2024.107357_bib0004","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/CCM.0000000000005298","article-title":"Descriptive epidemiology and outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2012-2019","volume":"50","author":"Zilberberg","year":"2022","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijid.2024.107357_bib0005","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.chest.2018.12.024","article-title":"A novel algorithm to analyze epidemiology and outcomes of carbapenem resistance among patients with hospital-acquired and ventilator-associated pneumonia: a retrospective cohort study","volume":"155","author":"Zilberberg","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.ijid.2024.107357_bib0006","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.3389\/fmicb.2019.02240","article-title":"Crisis of antimicrobial resistance in China: now and the future","volume":"10","author":"Qu","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijid.2024.107357_bib0007","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2024.107357_bib0008","unstructured":"US Food and Drug Administration. RECARBRIO\u2122 (imipenem, cilastatin, and relebactam) for injection, for intravenous use. Prescribing information. Rahway, NJ, USA: Merck Sharp & Dohme LLC; 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212819s002lbl.pdf [accessed 08 January 2025]."},{"key":"10.1016\/j.ijid.2024.107357_bib0009","unstructured":"European Medicines Agency. Recarbrio (imipenem\/cilastatin\/relebactam): an overview of recarbrio and why it is authorised in the EU; 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/recarbrio-epar-product-information_en.pdf [accessed 08 January 2025]."},{"key":"10.1016\/j.ijid.2024.107357_bib0010","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2024.107357_bib0011","doi-asserted-by":"crossref","first-page":"668","DOI":"10.37201\/req\/102.2021","article-title":"In vitro activity of imipenem\/relebactam against Gram-negative clinical isolates in two Spanish tertiary hospitals","volume":"34","author":"Pe\u00f1uelas","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijid.2024.107357_bib0012","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jac\/dky107","article-title":"In vitro activity of imipenem\/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme","volume":"73","author":"Karlowsky","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2024.107357_bib0013","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/147323000903700336","article-title":"Serious antimicrobial resistance status of pathogens causing hospital-acquired lower respiratory tract infections in North China","volume":"37","author":"Wang","year":"2009","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ijid.2024.107357_bib0014","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.ijid.2024.107357_bib0015","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijid.2024.107357_bib0016","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2307\/3001616","article-title":"Some methods for strengthening the common \u03c72 tests","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"10.1016\/j.ijid.2024.107357_bib0017","unstructured":"US Food and Drug Administration. Non-inferiority trials to establish effectiveness: guidance for industry; 2016. https:\/\/www.fda.gov\/media\/78504\/download [accessed 08 January 2025]."},{"key":"10.1016\/j.ijid.2024.107357_bib0018","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/cts.13158","article-title":"Population pharmacokinetic\/pharmacodynamic assessment of imipenem\/cilastatin\/relebactam in patients with hospital-acquired\/ventilator-associated bacterial pneumonia","volume":"15","author":"Patel","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ijid.2024.107357_bib0019","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2024.107357_bib0020","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/bcp.14204","article-title":"Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin","volume":"86","author":"Bhagunde","year":"2020","journal-title":"Br J Clin Pharmacol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224004326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224004326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T11:23:29Z","timestamp":1742037809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971224004326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":20,"alternative-id":["S1201971224004326"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2024.107357","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem\/cilastatin\/relebactam (IMI\/REL) vs piperacillin\/tazobactam (PIP\/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2024.107357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. and The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"107357"}}